ArticleScientific reports2026
Identification of a novel real-time PCR reference gene panel for EA.hy926 endothelial cells in different growth States and with DHA treatment.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Endothelial dysfunction underlies the pathogenesis of many diseases, including atherosclerosis, diabetes, and kidney failure. The EA.hy926 cell line is one of the most widely used human macrovascular endothelial cell models, and has been shown to enter both dysfunctional- and quiescent-like states. However, there are no validated housekeeping genes (HKGs) for EA.hy926 cells, especially suitable for different growth states and fatty acid treatments. Therefore, we screened transcriptomic data of EA.hy926 cells in their growing and quiescent states and after treatment with or without docosahexaenoic acid (DHA), and identified 18 candidate HKGs. Together with eight other commonly used HKGs and one HKG identified from databases, the stability of the 27 candidate HKGs were analyzed with five algorithms: deltaCt, BestKeeper, geNorm, NormFinder, and RefFinder, using the RT-qPCR results of EA.hy926 cells under 4 different growth conditions. The comprehensive ranking results from RefFinder suggested that the top two most stable genes were CAPZB and FBXO7, whereas the least stable commonly used HKGs were RNA18S and ACTB. The suitability of these genes as HKGs for EA.hy926 cells in different growth states and in response to DHA treatment were validated in relation to the expression of selective endothelial markers. The RT-qPCR validation results confirmed that normalization with CAPZB + FBXO7 provided greater sensitivity than the commonly used HKGs in detecting the expression difference of those endothelial markers under different conditions (growth state × DHA treatment). This novel panel of HKGs is available for future studies of EA.hy926 cell responses to different growth states and/or following DHA treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.